BioMarin Pharmaceutical Inc.

Valuation Analysis

About the Company

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It

BioMarin Pharmaceutical Inc. Stock at a Glance

BioMarin Pharmaceutical Inc. (BMRN) is currently trading at $55.95 with a market capitalization of $10.8B. The trailing P/E ratio stands at 40.25x, with a forward P/E of 8.66x. The 52-week range spans from $49.26 to $66.28; the current price is 15.6% below the yearly high. Year-over-year revenue growth stands at +2.8%. The net profit margin stands at 8.29%.

💰 Dividend

BioMarin Pharmaceutical Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

26 analysts rate BioMarin Pharmaceutical Inc. (BMRN) on consensus: Buy. The average price target is $87.85, implying +57.01% from the current price. Analyst price targets range from $50.00 to $120.00.

BioMarin Pharmaceutical Inc.: The Investment Case in Detail

BioMarin Pharmaceutical Inc. (BMRN) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

The combination of a 51.16% gross margin and 18% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 57.01% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue growth has slowed to just 2.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.69, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 8.66x is meaningfully below the trailing 40.25x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 57.01% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.02%).

Trading Data

Related Stocks in the Same Sector

Where can I buy BioMarin Pharmaceutical Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.